Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study provides initial insights into the use of JAK inhibitors for CTCL, reporting some cases of symptom improvement, but highlights the need for further research on their association with CTCL development and safety.

In this real-world study, JAK inhibitors like abrocitinib and tofacitinib led to substantial hair regrowth in 61% of alopecia areata patients over a median of 16 months, with 75% of non-responders achieving regrowth after switching medications; however, two serious adverse events were noted.

This literature review found that Janus kinase inhibitors may help achieve remission in patients with refractory primary neutrophilic cicatricial alopecias, though data is limited to small case series and reports.

This study found that inhibiting the ATR kinase with VE-822 impairs DNA repair capability in quiescent human keratinocytes exposed to solar-simulated UV radiation, suggesting ATR's critical role in facilitating effective DNA damage repair and cellular recovery under UV stress conditions.

In this study, xerosis and pruritus were common skin issues in pediatric chronic kidney disease patients, with xerosis linked to lower hemodialysis efficacy and higher white blood cells, and pruritis associated with higher hemoglobin levels.

Certain NK cell changes in blood may indicate alopecia areata progression.

This research investigated how moisture absorption impacts human hair structure, finding that moisture sorption kinetics reveal insights into chain entanglement and structural changes due to cosmetic treatments, while also quantifying the influence of sample weight and fiber density on the sorption process.

Pallister-Killian Syndrome is a complex genetic disorder requiring coordinated care and genetic counseling.

In this experimental study, the researchers observed that Platycladus orientalis leaf extract promoted hair growth by enhancing dermal papilla cell proliferation and increasing growth factor expression, particularly through ACK1 activation and modulation of Wnt/β-catenin signaling pathways in cultured human cells and a 12-week topical application.

In this case report, a 9-year-old with alopecia areata experienced full hair regrowth after six months of oral tofacitinib, with no recurrence or significant side effects for a year post-treatment.

In this retrospective study, researchers found that baricitinib was effective for treating moderate to severe alopecia areata, with response rates in 24 patients comparable to existing real-world data, and no new safety concerns were identified.

This review concluded that oral tofacitinib and adalimumab are promising treatments for cicatricial alopecia, showing effectiveness in improving signs and symptoms but requiring regular monitoring for adverse effects. The authors emphasize the need for further extensive studies to solidify these findings.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This study reports that adjusting the valence states of Mo in Pluronic F127-coated MoO3-x nanozymes enhances their selective H2O2-related catalytic activity, showing promise in acute kidney injury treatment and enabling real-time monitoring of therapy effectiveness through ROS-responsive photoacoustic imaging.

This study reports that JAK inhibitors were effective in inducing remission in ulcerative colitis patients and presented an acceptable safety profile with a range of manageable side effects.

This study reports the case of an elderly patient with a keratosis pilaris-like skin eruption after beginning treatment with imatinib for chronic myeloid leukemia, discussing similar skin reactions to BCR-ABL inhibitors and exploring potential mechanisms behind these adverse cutaneous reactions.

In this study, researchers found that ex vivo and in vivo administration of the TYK2 inhibitor BMS-986202 prevented immune privilege collapse and promoted hair regrowth in models of alopecia areata, suggesting this approach may offer a new therapeutic avenue deserving of clinical investigation.

In this study, treatment with oral JAK inhibitors was associated with improved disease outcomes in 80.6% of patients with refractory lichen planopilaris over a mean duration of 5 months.

This study found that oral Janus kinase inhibitors were effective in treating alopecia areata, with a clinical response rate of 48.3%, though further research is needed to assess long-term effects.

This review discusses the potential role of Garudan kizhangu ennai, a polyherbal Siddha formulation, in managing alopecia areata and highlights its various pharmacological properties, although further clinical studies are needed to confirm its efficacy.

This study found that escin acts as a natural agonist of the Wnt/β-catenin signaling pathway in cultured human dermal papilla cells by promoting the degradation of GSK-3β, highlighting its potential therapeutic use for conditions like androgenetic alopecia and vitiligo.

This study observed that among UK alopecia areata patients seeking JAK inhibitor treatments before public funding, many sourced medication from abroad due to high costs, with variable response rates and significant reliance on social media for information on accessing treatments.

This study found that JAK1 and JAK2 inhibitors increase β-catenin activity in human hair follicle cells, suggesting an additional therapeutic mechanism for treating severe alopecia areata.

In this study, a 24-year-old patient with severe alopecia areata showed an excellent clinical response to the JAK inhibitor tofacitinib after one month, following unsuccessful previous treatments.

This study observes that TYK2 inhibition with BMS-986202 may extend hair follicle growth phases and decrease inflammatory cell markers in alopecia areata, suggesting potential for clinical application.

This study found that three protocols for generating Titan cells in vitro from Candida neoformans vary in their kinetics and transcriptomic profiles, pointing to differences which could impact further research.

This case report details a 37-year-old woman with alopecia areata who experienced significant hair regrowth after psychological stress-triggered hair loss, following treatment with topical corticosteroids and tofacitinib.

This study found that a TYK2 inhibitor, BMS-986202, may restore immune privilege in hair follicles and promote hair regrowth in a humanized alopecia areata mouse model by inhibiting IL-12-mediated signaling.

This article outlines the scope, publication standards, and authorship responsibilities of the International Journal of KIU, but reports no new research results.

This article reviews the mode of action, efficacy, and safety of Janus kinase inhibitors in autoimmune dermatological conditions but reports no new clinical results.